Charcot-Marie-Tooth type IA (CMT1A) is the most prevalent hereditary peripheral neuropathy. Demyelination of peripheral nerves is the hallmark of CMT1A. Ascorbic acid has been shown to have a favorable influence on myelination in in vitro studies and in a mouse model for CMT1A. We will study the efficacy and safety of ascorbic acid treatment in young patients with CMT1A.

Charcot-Marie-Tooth type 1A (CMT1A), or hereditary motor and sensory neuropathy type Ia (HMSN Ia), is an autosomal dominant disease, most often caused by a 1.5 Mb duplication of chromosome 17, giving rise to three copies of the peripheral myelin protein 22 gene (PMP22). Mutations in this gene rarely cause CMT1A. It is a primarily demyelinating neuropathy, as has been shown in nerve conduction studies and in histopathological investigations. The conduction velocities of peripheral nerves are already slowed at the age of five years. Longitudinal data show that these conduction velocities do not change during life, indicating that the degree of demyelination is rather constant during life.

CMT1A is characterized clinically by distal muscle weakness and wasting, legs more than arms, impaired distal sensation, and reduced or absent reflexes. Moreover, foot and hand deformities are often encountered. In childhood, disease progression has been shown. In adults, there are indications for disease progression, but properly conducted longitudinal studies are awaited. Cross-sectional studies show that disease severity in adults is variable: a group of CMT1A patients is asymptomatic (5-10%), whereas other patients are wheelchair dependent (5-10%), still most have the classical CMT phenotype. Therapy is symptomatic and aims at maintaining functional possibilities and learning compensation mechanisms. There is no medication available that stabilizes or improves the clinical signs and symptoms.

Ascorbic acid is needed in in vitro studies for proper myelination of axons (in cultures containing serum). Recently, in a mouse model for CMT1A it has been shown that ascorbic acid improves the CMT1A phenotype. Mice (2-4 months old) treated with ascorbic acid once a week during three months showed an increase in the percentage of myelinating nerve fibers and showed better results in locomotor tests.

In this phase 2 study we will study the efficacy and safety of ascorbic acid in young patients with CMT1A. We will investigate whether ascorbic acid induces remyelination by measuring the nerve conduction of a peripheral nerve during a one year study period. CMT1A patients aged 12 years or older may cooperate sufficiently in nerve conduction studies. We include young patients, as clinical signs and symptoms especially develop relatively early in life. These signs and symptoms are due to axonal dysfunction, secondary to the demyelination. This is why we will investigate additionally whether there is an effect of ascorbic acid treatment on axonal function, strength and disabilities.

Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time

Medication that may cause a neuropathy

Chronic alcohol abuse

Due to study medication (ascorbic acid):

Regular use of vitamin C

Clinical or echographic signs of nephrolithiasis

Reduced glomerular filtration rate

Iron overload

No regular dental control at the dentist

Pregnancy or active pregnancy wish for women

Due to study design and primary outcome:

Not signing the informed consent

Psychiatric co-morbidity which may influence compliance

Not being comfortable during nerve conduction studies of the median nerve

A too small CMAP amplitude of the abductor pollicis brevis muscle for a proper determination of the nerve conduction velocity of the median nerve

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00271635

Locations

Netherlands

Department of Neurology Academic Medical Center University of Amsterdam

Amsterdam, P.O.Box 22660, Netherlands, 1100 DD

Sponsors and Collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Investigators

Principal Investigator:

C. Verhamme, MD

Department of Neurology, Academic Medical Center, University of Amsterdam

Principal Investigator:

M. Vermeulen, MD, PhD

Department of Neurology, Academic Medical Center, University of Amsterdam

Principal Investigator:

F. Baas, MD, PhD

Department of Neurology, Academic Medical Center, University of Amsterdam

Principal Investigator:

R. de Haan, MD, PhD

Department of Neurology, Academic Medical Center, University of Amsterdam

Principal Investigator:

M. de Visser, MD, PhD

Department of Neurology, Academic Medical Center, University of Amsterdam

Principal Investigator:

I. N van Schaik, MD, PhD

Department of Neurology, Academic Medical Center, University of Amsterdam